诊断准确性研究报告指南(Standards for Reporting of Diagnostic Accuracy,STARD)是用于规范诊断试验的报告,其最新版于2015年发布。本文主要介绍了STARD 2015指南的报告清单和研究流程图。我们期望国内同行借鉴STARD 2015指南开展诊...诊断准确性研究报告指南(Standards for Reporting of Diagnostic Accuracy,STARD)是用于规范诊断试验的报告,其最新版于2015年发布。本文主要介绍了STARD 2015指南的报告清单和研究流程图。我们期望国内同行借鉴STARD 2015指南开展诊断试验,不断提高我国诊断试验的报告质量。展开更多
诊断准确性研究是一类重要的临床研究类型,近年来在医学期刊中的发表数量逐渐增加,但其报道的规范性普遍较差,透明度不足,使读者难以充分评估其研究偏倚与临床应用价值。诊断准确性研究报告规范(Standards for Reporting Diagnostic Acc...诊断准确性研究是一类重要的临床研究类型,近年来在医学期刊中的发表数量逐渐增加,但其报道的规范性普遍较差,透明度不足,使读者难以充分评估其研究偏倚与临床应用价值。诊断准确性研究报告规范(Standards for Reporting Diagnostic AccuracyStudies,STARD)于2003年问世,2015年更新,是国际上公认的诊断准确性研究的报告规范。虽然国内早在2006年即翻译并引入STARD,但至今医学期刊编辑和作者对其重视仍然不够,甚至不甚了解。鉴于此,本文结合文献和笔者的工作经验,回顾STARD的产生、发展和主要内容,建议临床医学期刊编辑在审读诊断准确性研究类论文时重视和合理应用STARD。展开更多
类固醇合成急性调节相关脂质转运蛋白3(steroidogenic acute regulatory protein related lipid transfer domain containing3,STARD3)是类固醇激素急性调节蛋白家族成员之一,参与细胞内胆固醇非囊泡转运过程。目前已有研究证明人类表...类固醇合成急性调节相关脂质转运蛋白3(steroidogenic acute regulatory protein related lipid transfer domain containing3,STARD3)是类固醇激素急性调节蛋白家族成员之一,参与细胞内胆固醇非囊泡转运过程。目前已有研究证明人类表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)阳性乳腺癌的STARD3基因可与HER2基因共扩增、共高表达,且STARD3表达水平与肿瘤转移、局部复发和较短的总生存期呈正相关。本文就STARD3调节细胞内胆固醇分配过程以及与HER2阳性乳腺癌的关系进行综述,并分析其可能的致病机制。展开更多
Lenvatinib is widely used as a first-line chemotherapy for advanced hepatocellular carcinoma(HCC),a highly metastatic and recurrent cancer.However,HCC cells often develop resistance to lenvatinib,thus reducing its eff...Lenvatinib is widely used as a first-line chemotherapy for advanced hepatocellular carcinoma(HCC),a highly metastatic and recurrent cancer.However,HCC cells often develop resistance to lenvatinib,thus reducing its efficacy.This study aims to investigate the impact of STARD4,a crucial cholesterol transporter,on HCC growth and lenvatinib resistance,as well as explore the involvement of the EGFR/PI3K/AKT signaling pathway in STARD4's role.Analysis of clinical samples from HCC patients revealed increased expression of both STARD4 and EGFR in tumor tissues,with a strong correlation between STARD4 expression and malignancy progression.In vitro and in vivo studies demonstrated that STARD4 promoted HCC growth and hindered lenvatinib's anti-tumor effect,while STARD4 down-regulation exerted opposite effects.Further investigation revealed that depletion of STARD4 increased cholesterol accumulation in the plasma membrane,resulting in reduced EGFR phosphorylation.Moreover,cholesterol depletion attenuated these effects,suggesting STARD4 activates EGFR/PI3K/AKT signaling in a cholesterol-dependent manner.To elucidate the underlying mechanism of lenvatinib resistance,we established the lenvatinib-resistant HCC cell lines and found increased stimulation of both STARD4 and EGFR signaling.Furthermore,the EGFR inhibitor erlotinib suppressed the promotion of HCC progression by STARD4,reinforcing its role in activating the EGFR/PI3K/AKT pathway.In conclusion,this study demonstrates that STARD4 enhances HCC growth and lenvatinib resistance by regulating cholesterol homeostasis and activating the EGFR/PI3K/AKT pathway.These findings suggest STARD4 as a potential molecular biomarker for predicting lenvatinib resistance and as a therapeutic target in HCC treatment.展开更多
文摘诊断准确性研究报告指南(Standards for Reporting of Diagnostic Accuracy,STARD)是用于规范诊断试验的报告,其最新版于2015年发布。本文主要介绍了STARD 2015指南的报告清单和研究流程图。我们期望国内同行借鉴STARD 2015指南开展诊断试验,不断提高我国诊断试验的报告质量。
文摘诊断准确性研究是一类重要的临床研究类型,近年来在医学期刊中的发表数量逐渐增加,但其报道的规范性普遍较差,透明度不足,使读者难以充分评估其研究偏倚与临床应用价值。诊断准确性研究报告规范(Standards for Reporting Diagnostic AccuracyStudies,STARD)于2003年问世,2015年更新,是国际上公认的诊断准确性研究的报告规范。虽然国内早在2006年即翻译并引入STARD,但至今医学期刊编辑和作者对其重视仍然不够,甚至不甚了解。鉴于此,本文结合文献和笔者的工作经验,回顾STARD的产生、发展和主要内容,建议临床医学期刊编辑在审读诊断准确性研究类论文时重视和合理应用STARD。
文摘类固醇合成急性调节相关脂质转运蛋白3(steroidogenic acute regulatory protein related lipid transfer domain containing3,STARD3)是类固醇激素急性调节蛋白家族成员之一,参与细胞内胆固醇非囊泡转运过程。目前已有研究证明人类表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)阳性乳腺癌的STARD3基因可与HER2基因共扩增、共高表达,且STARD3表达水平与肿瘤转移、局部复发和较短的总生存期呈正相关。本文就STARD3调节细胞内胆固醇分配过程以及与HER2阳性乳腺癌的关系进行综述,并分析其可能的致病机制。
基金supported by the Guangdong Basic and Applied Basic Research Foundation of China(No.2023A1515012595,2024A1515012743)Nanfang Hospital Dean's Fund(No.2022A010)+1 种基金Wu Jieping Medical Foundation(No.320.6750.2023-06-18)Hospital Pharmacy Research Foundation of the Guangdong Liver Disease Association of China(No.2023gdsgzbzd01).
文摘Lenvatinib is widely used as a first-line chemotherapy for advanced hepatocellular carcinoma(HCC),a highly metastatic and recurrent cancer.However,HCC cells often develop resistance to lenvatinib,thus reducing its efficacy.This study aims to investigate the impact of STARD4,a crucial cholesterol transporter,on HCC growth and lenvatinib resistance,as well as explore the involvement of the EGFR/PI3K/AKT signaling pathway in STARD4's role.Analysis of clinical samples from HCC patients revealed increased expression of both STARD4 and EGFR in tumor tissues,with a strong correlation between STARD4 expression and malignancy progression.In vitro and in vivo studies demonstrated that STARD4 promoted HCC growth and hindered lenvatinib's anti-tumor effect,while STARD4 down-regulation exerted opposite effects.Further investigation revealed that depletion of STARD4 increased cholesterol accumulation in the plasma membrane,resulting in reduced EGFR phosphorylation.Moreover,cholesterol depletion attenuated these effects,suggesting STARD4 activates EGFR/PI3K/AKT signaling in a cholesterol-dependent manner.To elucidate the underlying mechanism of lenvatinib resistance,we established the lenvatinib-resistant HCC cell lines and found increased stimulation of both STARD4 and EGFR signaling.Furthermore,the EGFR inhibitor erlotinib suppressed the promotion of HCC progression by STARD4,reinforcing its role in activating the EGFR/PI3K/AKT pathway.In conclusion,this study demonstrates that STARD4 enhances HCC growth and lenvatinib resistance by regulating cholesterol homeostasis and activating the EGFR/PI3K/AKT pathway.These findings suggest STARD4 as a potential molecular biomarker for predicting lenvatinib resistance and as a therapeutic target in HCC treatment.
